Baxter Bros Inc. Decreases Holdings in Solventum Co. (NYSE:SOLV)

Baxter Bros Inc. lowered its stake in shares of Solventum Co. (NYSE:SOLV) by 19.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,016 shares of the company’s stock after selling 1,177 shares during the period. Baxter Bros Inc.’s holdings in Solventum were worth $331,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Modus Advisors LLC purchased a new stake in Solventum during the 4th quarter worth approximately $25,000. Stonebridge Financial Group LLC acquired a new position in Solventum during the fourth quarter worth about $26,000. Crews Bank & Trust purchased a new stake in Solventum during the 4th quarter valued at about $32,000. True Wealth Design LLC raised its holdings in Solventum by 23,550.0% in the 3rd quarter. True Wealth Design LLC now owns 473 shares of the company’s stock valued at $33,000 after acquiring an additional 471 shares during the last quarter. Finally, Synergy Asset Management LLC purchased a new position in Solventum in the 4th quarter worth approximately $35,000.

Analyst Ratings Changes

SOLV has been the subject of a number of analyst reports. Wells Fargo & Company upped their price target on Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a research report on Friday, February 28th. Piper Sandler raised their target price on Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research note on Friday, February 28th. Morgan Stanley boosted their price target on shares of Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a research report on Wednesday, March 5th. The Goldman Sachs Group raised their price objective on shares of Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a research report on Monday, March 3rd. Finally, Mizuho increased their price target on shares of Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, March 3rd. One analyst has rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $79.86.

Solventum Price Performance

Solventum stock opened at $74.24 on Tuesday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The company has a market capitalization of $12.84 billion and a price-to-earnings ratio of 27.00. The company’s 50 day simple moving average is $75.29 and its 200-day simple moving average is $71.67. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $85.92.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.